It is well recognised that CMV infection may persist 25 . The optimal time to avoid pregnancy after CMV infection is not known. However postponing pregnancy for a period of 6-12 months may be advisable after primary CMV infection, as periconception infection is also associated with fetal effects 4,26 .
There is low awareness of congenital cytomegalovirus (CMV) in Australia. Routine pregnancy serological screening for CMV is not recommended, but all pregnant women should be given advice about CMV prevention. Obstetricians may be asked to see a pregnant woman when serology suggests CMV infection or when features of fetal infection are present on ultrasound. If maternal CMV infection is confirmed, the timing of infection (pre-pregnancy or gestation of pregnancy), must be determined to predict the fetal risks. In addition, it is important to establish whether maternal infection is primary or reactivation. If there is fetal infection, ultrasound can be used to attempt to establish whether the fetus may have been affected. Serial serology, CMV IgG avidity, maternal viraemia (using serum PCR), amniotic fluid CMV PCR, serial fetal ultrasounds, and possibly fetal MRI (magnetic resonance imaging) are investigations that may be useful to predict neonatal outcomes. Timely and accurate counselling is important to optimise maternal and neonatal management.
Primary maternal CMV infection in the first trimester of pregnancy has the greatest risk of adverse fetal and infant outcomes 1 . These include hearing loss, adverse neurodevelopmental outcomes and in severe cases, fetal death 2 . In first trimester CMV infection, approximately 35% of fetuses will develop CMV infection 3, 4 . Of these, only 25% will have an adverse outcome due to the infection 4, 5 . Thus, it is estimated 10% of women with a primary CMV infection in early pregnancy will have a fetus or infant with an adverse outcome 3 . The rate of fetal infection increases with gestation, but the rate of fetal and infant adverse outcomes decreases with gestation 6 . The rates of adverse outcomes with peri-conception CMV are lower still than in the first trimester 4 . Furthermore, the risks of fetal infection and adverse outcomes are lower with CMV reactivation or re-infection, than with primary infection 7 .
Routine serologic CMV screening in pregnancy is not recommended in Australia 8, 9 . The potential benefits of routine screening are outweighed by the harms 10 . Screening women at high risk of acquiring CMV infection, ideally pre-pregnancy, may be considered 8 . In . Low avidity suggests infection within the previous 3 months. Change in avidity may also be used to predict timing of infection 13 . Maternal CMV viraemia using polymerase chain reaction (PCR) may be also useful to establish the time of infection 14 .
Once the diagnosis of primary maternal CMV in pregnancy, or periconception is established, determining fetal infection will assist in predicting infant outcomes. Amniotic fluid CMV PCR is the most Human cytomegalovirus (HCMV) infection is highly speciesspecific, which means that it is unable to productively infect Table 1) .
Transplacental transmission and neonatal infections
The placentae of the guinea-pig and the rhesus macaque are structurally similar to the human placenta 1 . Experimental infections with RhCMV and GPCMV result in foetal infection, with clinical manifestations that include CNS involvement and (for GPCMV) sensorineural hearing loss (SNHL) 2, 6, 7 . Systemic maternal infection causes syndromes deleterious for the developing foetus, (e.g.
intrauterine growth restriction) with the incidence of foetal morbidity and mortality being highest when transmission occurs during early gestation 2, 3 . These key pathological features are similar to congenital HCMV infection 15 .
Despite poor transplacental transmission of MCMV in the laboratory setting, direct injection into the foetus or the newborn pup has been shown to mimic HCMV-induced congenital disease 12, 13 . Similar to RhCMV, the susceptibility of neuronal stem cells to MCMV infection is maturation stage-dependent, with a rapid resistance to infection of the brain developing after birth 16 . MCMV also infects the auditory nerve spiral ganglion and cochlea of newborn pups with measurable cytopathic effects and neuronal loss, and thus offers an amenable model for studying viral and host factors that contribute to SNHL 17 .
Evaluation of antiviral therapies to ameliorate effects of congenital infection
Current antiviral therapies for HCMV target the viral replicative machinery (e.g. ganciclovir, valganciclovir, foscarnet and cidifivor) 18, 19 . However, due to their toxicity, none are licenced for use during pregnancy and only ganciclovir/valganciclovir (that target the
